Is Spironolactone a Beta-Blocker or ACE Inhibitor?

Spironolactone is neither a beta-blocker nor an ACE inhibitor. It belongs to an entirely different drug class called mineralocorticoid receptor antagonists (MRAs), sometimes also grouped under potassium-sparing diuretics. The confusion is understandable because spironolactone is often prescribed for the same conditions that beta-blockers and ACE inhibitors treat, and all three frequently appear together on the same prescription list for a patient with heart failure or high blood pressure.

How Spironolactone Actually Works

Spironolactone blocks a hormone called aldosterone. Aldosterone is produced by the adrenal glands and tells the kidneys to hold on to sodium and water while dumping potassium. By sitting on the aldosterone receptor and preventing aldosterone from doing its job, spironolactone causes the body to release sodium and water (lowering blood pressure and reducing fluid buildup) while holding on to potassium. This is why it earns the “potassium-sparing” label, a trait that distinguishes it sharply from most other diuretics, which tend to deplete potassium.

Research in animal models has shown that spironolactone directly reduces the abundance of specific sodium-transporting proteins in the kidney, particularly the channels that aldosterone would normally ramp up in response to a low-salt diet.¹ That molecular action is fundamentally different from the way beta-blockers or ACE inhibitors lower blood pressure.

Beyond sodium and water balance, aldosterone also drives inflammation and scarring (fibrosis) in the heart and blood vessels. Blocking it with spironolactone has protective effects on the heart that go beyond simply removing extra fluid. This dual role, as both a diuretic and a heart-protective agent, is a big part of why spironolactone shows up so often in cardiology.

Where Beta-Blockers and ACE Inhibitors Fit In

Beta-blockers work by blocking beta-adrenergic receptors, the docking sites for adrenaline and related stress hormones on the heart and blood vessels. When those receptors are blocked, the heart beats more slowly and with less force, and blood vessels relax somewhat. Propranolol is a classic example.² ACE inhibitors, on the other hand, interrupt the renin-angiotensin-aldosterone system (RAAS) by preventing the enzyme that converts angiotensin I into angiotensin II, a potent blood-vessel constrictor. Less angiotensin II means less vessel constriction and, downstream, less aldosterone release.

Here is the overlap that creates confusion: the RAAS is a cascade, and both ACE inhibitors and spironolactone act on it, just at different points. ACE inhibitors work near the top of the cascade, cutting off the production of angiotensin II. Spironolactone works near the bottom, blocking aldosterone’s effects directly at the receptor. ACE inhibitors and ARBs (angiotensin receptor blockers) are highly effective, but they cannot completely suppress the RAAS on their own.³ Aldosterone levels sometimes creep back up despite ACE inhibitor therapy, a phenomenon called “aldosterone breakthrough.” Spironolactone catches what slips through.

Beta-blockers, by contrast, act on a completely different signaling pathway: the sympathetic nervous system rather than the RAAS. They slow adrenaline’s effects on the heart. So while a patient might take all three drugs for heart failure, each one is pulling a different lever.

Heart Failure and the Landmark RALES Trial

Spironolactone’s reputation in cardiology rests largely on a single landmark trial published in 1999 called RALES (Randomized Aldactone Evaluation Study). In patients with severe heart failure who were already taking standard therapy, adding spironolactone cut the risk of death by about 30 percent. The death rate was 46 percent in the placebo group compared with 35 percent in the spironolactone group, and hospitalizations for worsening heart failure dropped by 35 percent.⁴ The trial was stopped early because the benefit was so clear.

That result made spironolactone a cornerstone of severe heart failure treatment and was interpreted as evidence that blocking aldosterone added something that ACE inhibitors alone could not provide.⁵ The RALES population had advanced disease (New York Heart Association class III–IV), and the magnitude of benefit was striking for a drug that cost very little.

Subsequent work in patients with milder heart failure has been less clear-cut. One study found that adding spironolactone to patients already on both an ACE inhibitor and a beta-blocker reduced some markers of heart stress but also worsened kidney function and quality of life, leaving the overall risk-benefit ratio uncertain in that population.⁶ An observational study of outpatients with reduced heart function also could not confirm a survival benefit from adding spironolactone on top of both ACE inhibitors and beta-blockers.⁷ The evidence is strongest in severe heart failure; in milder forms, the picture is more nuanced.

Resistant Hypertension

For people whose blood pressure remains stubbornly high despite taking three or more drugs (including a diuretic), spironolactone has emerged as the most effective add-on option. The PATHWAY-2 trial tested spironolactone head-to-head against bisoprolol (a beta-blocker) and doxazosin (an alpha-blocker) in patients with resistant hypertension. Spironolactone lowered home systolic blood pressure by about 9 mmHg more than placebo and outperformed both bisoprolol and doxazosin by roughly 4 to 4.5 mmHg.⁸ The benefit was most pronounced in patients with lower levels of renin, a hormone that initiates the RAAS cascade, suggesting that resistant hypertension often has an aldosterone-driven component that standard drugs miss.

A separate randomized trial in patients with resistant hypertension confirmed the systolic blood pressure-lowering effect, reporting a roughly 5 to 7 mmHg drop in daytime ambulatory readings with add-on spironolactone compared to placebo.⁹ Mechanistic substudies of PATHWAY-2 further supported the idea that spironolactone reduces blood pressure substantially more than conventional antihypertensive drugs in this particular population.¹⁰

Spironolactone is also uniquely suited for primary aldosteronism, a condition in which the adrenal glands overproduce aldosterone. In these patients the drug directly targets the root cause. A recent study from a specialized center found that even low doses of spironolactone, combined with other blood pressure drugs, achieved good blood pressure control in primary aldosteronism while minimizing side effects.¹¹

Anti-Androgenic Effects Beyond the Heart

One of the more surprising aspects of spironolactone is its role in dermatology and hormonal medicine. The drug was not designed to affect androgens (male sex hormones), but its steroid-based chemical structure happens to block androgen receptors and interfere with testosterone production. This “side effect” turned into a therapeutic use. Spironolactone is now widely prescribed off-label for hormonal acne, excess facial or body hair (hirsutism), and female-pattern hair loss, particularly in people with polycystic ovary syndrome (PCOS).¹²

These anti-androgenic properties also make spironolactone one of the more commonly used medications in feminizing hormone therapy for transgender women, where the goal is to suppress testosterone to female-range levels. It is typically combined with estrogen. A randomized controlled trial comparing spironolactone with cyproterone acetate (another anti-androgen) in transgender women noted that both drugs are commonly used for this purpose, though comparative data on their effectiveness remain limited.¹³

No beta-blocker or ACE inhibitor has these hormonal effects. This is one of the clearest ways to see that spironolactone is a fundamentally different kind of drug, even though it often shares shelf space with them on a prescription list.

Side Effects to Watch For

The flip side of holding on to potassium is that spironolactone can raise potassium levels dangerously high, a condition called hyperkalemia. This risk is amplified when the drug is combined with ACE inhibitors or ARBs, which also tend to raise potassium. A population-based study of heart failure patients found that spironolactone use was associated with a strikingly elevated risk of hyperkalemia, with an odds ratio above 13 compared with non-use.¹⁴ That does not mean most patients on spironolactone will develop dangerous potassium levels, but it does mean regular blood tests to monitor potassium and kidney function are standard practice when this drug is prescribed.

A large recent analysis of heart failure patients starting spironolactone found that combining it with sacubitril/valsartan (a newer heart failure drug) carried a lower risk of severe hyperkalemia than combining it with traditional ACE inhibitors or ARBs.¹⁵ The practical takeaway is that what you combine spironolactone with matters for safety, and newer combination regimens may carry less potassium risk than older ones.

The other well-known side effect is gynecomastia, or breast tissue enlargement in men. Spironolactone causes this by displacing androgens from their receptors and from sex-hormone-binding globulin, while also increasing estradiol production.¹⁶ When spironolactone was first developed in the late 1950s, these dose-dependent sexual side effects were recognized early and limited its long-term use in some patients.¹⁷ It was this shortcoming that drove decades of research toward more selective alternatives.

Newer Alternatives and How They Compare

Spironolactone’s hormonal side effects stem from its lack of selectivity: it blocks not only the mineralocorticoid receptor (where aldosterone acts) but also androgen and progesterone receptors. Two newer MRAs were developed specifically to avoid this problem.

Eplerenone, approved in the early 2000s, is more selective for the mineralocorticoid receptor and causes far fewer hormonal side effects like gynecomastia. However, it is less potent milligram for milligram and typically more expensive. Finerenone, the newest of the three, is a non-steroidal MRA. Because its chemical structure is not steroid-based, it avoids the androgen-receptor binding that causes spironolactone’s sexual side effects entirely.

A pharmacovigilance study covering 20 years of adverse-event reports confirmed these differences in a practical way: spironolactone was uniquely associated with serious hormonal events like gynecomastia and other sex-hormone-related issues, while finerenone lacked significant sex-hormone-related adverse events altogether.¹⁸

In terms of effectiveness, a network meta-analysis in patients with type 2 diabetes and chronic kidney disease found that spironolactone and finerenone were equally effective at reducing protein in the urine (a marker of kidney damage) and both outperformed eplerenone. But spironolactone carried the highest risk of hyperkalemia, while finerenone and eplerenone were significantly safer on that front.¹⁹ Finerenone, in other words, managed to match spironolactone’s kidney-protective potency without the elevated hyperkalemia risk. For patients who need aldosterone blockade but cannot tolerate spironolactone’s side effects, these newer options fill an important gap.

Why the Three Drug Classes End Up Together

The reason people encounter spironolactone alongside beta-blockers and ACE inhibitors so frequently is that modern heart failure treatment is built on layering drugs that target different systems simultaneously. A typical regimen for heart failure with reduced pumping function includes an ACE inhibitor or ARB (to block the RAAS higher up), a beta-blocker (to calm the sympathetic nervous system), and a mineralocorticoid receptor antagonist like spironolactone (to block aldosterone at the receptor level). Each drug addresses a different piece of the problem, and together they reduce hospitalizations and prolong life more than any single drug alone.

The same layering logic applies in resistant hypertension. Patients arrive at spironolactone because their blood pressure has not responded adequately to standard first-line drugs, which often include an ACE inhibitor or ARB, a calcium channel blocker, and a thiazide diuretic. Spironolactone’s ability to target the aldosterone pathway directly makes it a natural fourth agent in this scenario, and the PATHWAY-2 data showed it outperforms both a beta-blocker and an alpha-blocker when added to a three-drug regimen.

Seeing all three classes on one prescription label can understandably lead someone to assume they are interchangeable or at least closely related. They are not. They work through different receptors, affect different hormones, and carry different side-effect profiles. Swapping one for another would not produce the same result, because each is solving a different part of the cardiovascular puzzle.

How Spironolactone Came to Exist

Spironolactone’s story begins in the 1950s, shortly after aldosterone itself was identified in 1953. Researchers screened synthetic steroid compounds for their ability to counteract mineralocorticoid effects in laboratory animals, and a class of molecules called 17-spirolactone steroids proved effective.²⁰ Spironolactone entered clinical use before researchers fully understood the scope of its receptor interactions, which is how a drug designed to manage sodium balance ended up treating acne and aiding gender-affirming therapy decades later. Its chemical resemblance to steroid hormones, the very feature that gives it off-target androgenic effects, was simply a byproduct of being modeled on aldosterone’s own molecular shape. That initial design choice has shaped both its remarkable versatility and the side-effect limitations that newer, non-steroidal MRAs now aim to correct.